TY - JOUR
T1 - Targeting leukemia inhibitory factor in pancreatic adenocarcinoma
AU - Wang, Jing
AU - Karime, Christian
AU - Majeed, Umair
AU - Starr, Jason S.
AU - Borad, Mitesh J.
AU - Babiker, Hani M.
N1 - Funding Information:
HM Babiker is a Paul Calabresi Scholar at the Mayo Clinic Cancer Center and acknowledges the K-12 grant Program, K12CA090628. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Publisher Copyright:
© 2023 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2023
Y1 - 2023
N2 - Introduction: The Leukemia Inhibitory Factor (LIF) is a member of the interleukin-6 (IL-6) cytokine family. Known to induce differentiation of myeloid leukemia cells, evidence has accumulated supporting its role in cancer evolution through regulating cell differentiation, renewal, and survival. LIF has recently emerged as a biomarker and therapeutic target for pancreatic ductal adenocarcinoma (PDAC). The first in-human clinical trial has shown promising safety profile and has suggested a potential role for LIF inhibitor in combination regimen. Areas covered: Herein, we summarize, discuss, and give an expert opinion on the role of LIF in PDAC promotion, and its potential role as a biomarker and target of anti-cancer therapy. We conducted an exhaustive PubMed search for English-language articles published from 1 January 1970, to 1 August 2022. Expert opinion: PDAC carries a devastating prognosis for patients, highlighting the need for advancing drug development. The results of the phase 1 trial with MSC-1 demonstrated tolerability and safety but modest efficacy. Future research should focus on investigating LIF targets in combination with current standard-of-care chemotherapy, and immunotherapy can be a promising approach. Further, larger multicenter clinical trials are needed to define the use of LIF as a new biomarker in PDAC patients.
AB - Introduction: The Leukemia Inhibitory Factor (LIF) is a member of the interleukin-6 (IL-6) cytokine family. Known to induce differentiation of myeloid leukemia cells, evidence has accumulated supporting its role in cancer evolution through regulating cell differentiation, renewal, and survival. LIF has recently emerged as a biomarker and therapeutic target for pancreatic ductal adenocarcinoma (PDAC). The first in-human clinical trial has shown promising safety profile and has suggested a potential role for LIF inhibitor in combination regimen. Areas covered: Herein, we summarize, discuss, and give an expert opinion on the role of LIF in PDAC promotion, and its potential role as a biomarker and target of anti-cancer therapy. We conducted an exhaustive PubMed search for English-language articles published from 1 January 1970, to 1 August 2022. Expert opinion: PDAC carries a devastating prognosis for patients, highlighting the need for advancing drug development. The results of the phase 1 trial with MSC-1 demonstrated tolerability and safety but modest efficacy. Future research should focus on investigating LIF targets in combination with current standard-of-care chemotherapy, and immunotherapy can be a promising approach. Further, larger multicenter clinical trials are needed to define the use of LIF as a new biomarker in PDAC patients.
KW - EC359
KW - Leukemia inhibitory factor
KW - MSC-1
KW - biomarker
KW - pancreatic ductal adenocarcinoma
KW - therapeutic target
KW - tumor microencironment
UR - http://www.scopus.com/inward/record.url?scp=85153611363&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85153611363&partnerID=8YFLogxK
U2 - 10.1080/13543784.2023.2206558
DO - 10.1080/13543784.2023.2206558
M3 - Review article
C2 - 37092893
AN - SCOPUS:85153611363
SN - 1354-3784
VL - 32
SP - 387
EP - 399
JO - Expert Opinion on Investigational Drugs
JF - Expert Opinion on Investigational Drugs
IS - 5
ER -